Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2013

01.09.2013 | review

Personalized medicine for breast cancer: dream or reality?

verfasst von: Lina Pugliano, Dimitrios Zardavas, Martine Piccart, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The National Cancer Institute of the United States defines personalized medicine (PM) as “a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease” (National Cancer Institute, Dictionary of Cancer Terms) [1]. Consequently, the ultimate dream is the generation of a “molecular fingerprint” via a simple blood test or tumor sample that allows the physician to refine an individual patient’s prognosis, select the best possible therapeutic option, and minimize the toxicity from therapies by identification of distinct genetic markers. The enormous gains to patients and ultimately health care systems are unmistakable.
Literatur
1.
Zurück zum Zitat National Cancer Institute. Dictionary of Cancer Terms. National Cancer Institute. Dictionary of Cancer Terms.
2.
Zurück zum Zitat World Health Organization GLOBCAN. Cancer incidence, mortality and prevalence worldwide in 2008. World Health Organization GLOBCAN. Cancer incidence, mortality and prevalence worldwide in 2008.
3.
Zurück zum Zitat O’Shaughnessy J Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl. 3):20–90. O’Shaughnessy J Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl. 3):20–90.
4.
Zurück zum Zitat Balmaña J, Díez O, Rubio IT, Cardoso F EGWG BRCA 2 breast cancer. ESMO clinical practice guidelines. Ann Oncol. 2011;22:vi3–4. Balmaña J, Díez O, Rubio IT, Cardoso F EGWG BRCA 2 breast cancer. ESMO clinical practice guidelines. Ann Oncol. 2011;22:vi3–4.
5.
Zurück zum Zitat Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800.PubMedCrossRef Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800.PubMedCrossRef
6.
Zurück zum Zitat Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C. Molecular profiling: moving away from tumor philately. Sci Transl Med. 2010;2:47ps43. Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C. Molecular profiling: moving away from tumor philately. Sci Transl Med. 2010;2:47ps43.
7.
Zurück zum Zitat Wirapati P, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65.CrossRef Wirapati P, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65.CrossRef
8.
Zurück zum Zitat Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M. Prediction of late breast cancer recurrence by the ROR (PAM50) score in postmenopausal women in the TransATAC cohort. Ann Oncol. 2012;23:Abstr. 1201. Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M. Prediction of late breast cancer recurrence by the ROR (PAM50) score in postmenopausal women in the TransATAC cohort. Ann Oncol. 2012;23:Abstr. 1201.
9.
Zurück zum Zitat Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, Dietze O, Weber KE, Petry C, Kronenwett R, Rudas M, Knauer M, Gnant M, Filipits M. The EndoPredict score identifies late distant metastases in ER+/HER2– breast cancer patients. Cancer Res. 2012;72:Abstr. S4–3. Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, Dietze O, Weber KE, Petry C, Kronenwett R, Rudas M, Knauer M, Gnant M, Filipits M. The EndoPredict score identifies late distant metastases in ER+/HER2– breast cancer patients. Cancer Res. 2012;72:Abstr. S4–3.
10.
Zurück zum Zitat Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M. Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: a TransATAC Study. Cancer Res. 2012;72:Abstr. S1–9. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M. Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: a TransATAC Study. Cancer Res. 2012;72:Abstr. S1–9.
11.
Zurück zum Zitat Gnant M, Filipits M, Dubsky P, Rudas M, Balic M, Greil R, Ferree S, Cowens JW, Schaper C, NT Predicting risk for late metastasis: the PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial. Ann Oncol. 2013;24:Abstr. 530_PR. Gnant M, Filipits M, Dubsky P, Rudas M, Balic M, Greil R, Ferree S, Cowens JW, Schaper C, NT Predicting risk for late metastasis: the PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial. Ann Oncol. 2013;24:Abstr. 530_PR.
12.
Zurück zum Zitat Sestak I, Dowsett M, Sgroi D, Erlander M, Ferree S, Cowens J, Cuzick J. Comparison of five different scores for the prediction of late recirrence for oestrogen receptor-positive breast cancer. Ann Oncol. 2013;24:Abstr. 540_PR. Sestak I, Dowsett M, Sgroi D, Erlander M, Ferree S, Cowens J, Cuzick J. Comparison of five different scores for the prediction of late recirrence for oestrogen receptor-positive breast cancer. Ann Oncol. 2013;24:Abstr. 540_PR.
13.
Zurück zum Zitat Cardoso F, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26:729–35.PubMedCrossRef Cardoso F, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26:729–35.PubMedCrossRef
14.
Zurück zum Zitat Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26:721–28.PubMedCrossRef Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26:721–28.PubMedCrossRef
15.
Zurück zum Zitat Ma X-J, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11:R7. Ma X-J, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11:R7.
16.
Zurück zum Zitat Desmedt C, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14:5158–65.PubMedCrossRef Desmedt C, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14:5158–65.PubMedCrossRef
17.
Zurück zum Zitat Iwamoto T, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103:264–72.PubMedCrossRef Iwamoto T, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103:264–72.PubMedCrossRef
18.
Zurück zum Zitat Albain KS, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.PubMedCrossRef Albain KS, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.PubMedCrossRef
19.
Zurück zum Zitat Desmedt C, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29:1578–86.PubMedCrossRef Desmedt C, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29:1578–86.PubMedCrossRef
20.
Zurück zum Zitat Symmans WF, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28:4111–9.PubMedCrossRef Symmans WF, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28:4111–9.PubMedCrossRef
21.
Zurück zum Zitat Juul N, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010;11:358–65.PubMedCrossRef Juul N, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010;11:358–65.PubMedCrossRef
22.
Zurück zum Zitat Barretina J, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.PubMedCrossRef Barretina J, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.PubMedCrossRef
23.
Zurück zum Zitat Garnett MJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5.PubMedCrossRef Garnett MJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5.PubMedCrossRef
24.
Zurück zum Zitat Frueh FW, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28:992–8.PubMedCrossRef Frueh FW, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28:992–8.PubMedCrossRef
25.
Zurück zum Zitat Nowell SA, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005;91:249–58.PubMedCrossRef Nowell SA, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005;91:249–58.PubMedCrossRef
26.
Zurück zum Zitat Okishiro M, et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115:952–61.PubMedCrossRef Okishiro M, et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115:952–61.PubMedCrossRef
27.
Zurück zum Zitat Schroth W, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–36.PubMedCrossRef Schroth W, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–36.PubMedCrossRef
28.
Zurück zum Zitat Goetz MP, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013;19:500–7.PubMedCrossRef Goetz MP, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013;19:500–7.PubMedCrossRef
29.
Zurück zum Zitat Braun S, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802.PubMedCrossRef Braun S, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802.PubMedCrossRef
30.
Zurück zum Zitat Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt K. ACOSOG Z0010: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol. 2010;28:Abstr. CRA504. Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt K. ACOSOG Z0010: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol. 2010;28:Abstr. CRA504.
31.
Zurück zum Zitat Janni W, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res. 2011;17:2967–76.PubMedCrossRef Janni W, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res. 2011;17:2967–76.PubMedCrossRef
32.
Zurück zum Zitat Cristofanilli M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.PubMedCrossRef Cristofanilli M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.PubMedCrossRef
33.
Zurück zum Zitat Pierga J-Y, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23:618–24.PubMedCrossRef Pierga J-Y, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23:618–24.PubMedCrossRef
34.
Zurück zum Zitat Budd GT, et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403–9.PubMedCrossRef Budd GT, et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403–9.PubMedCrossRef
35.
Zurück zum Zitat De Giorgi U et al Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27:3303–11.PubMedCrossRef De Giorgi U et al Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27:3303–11.PubMedCrossRef
36.
Zurück zum Zitat Liu MC, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27:5153–9.PubMedCrossRef Liu MC, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27:5153–9.PubMedCrossRef
37.
Zurück zum Zitat Bidard F-C, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2010;21:729–33.PubMedCrossRef Bidard F-C, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2010;21:729–33.PubMedCrossRef
38.
Zurück zum Zitat Rack B, Schindlbeck C, Andergassen U, Lorenz R, Zwingers T, Schneeweiss A, Lichtenegger W, Beckmann M, Sommer H, Pantel K, Friese K, Janni W. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. San Antonio Breast Cancer Conference. 2010:Abstr. S6–5. Rack B, Schindlbeck C, Andergassen U, Lorenz R, Zwingers T, Schneeweiss A, Lichtenegger W, Beckmann M, Sommer H, Pantel K, Friese K, Janni W. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. San Antonio Breast Cancer Conference. 2010:Abstr. S6–5.
39.
Zurück zum Zitat Pierga J-Y, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004–10.PubMedCrossRef Pierga J-Y, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004–10.PubMedCrossRef
40.
Zurück zum Zitat Riethdorf S, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16:2634–45.PubMedCrossRef Riethdorf S, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16:2634–45.PubMedCrossRef
41.
Zurück zum Zitat Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers–blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8:142–50.PubMedCrossRef Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers–blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8:142–50.PubMedCrossRef
42.
Zurück zum Zitat McBride DJ, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes chromosome cancer. 2010;49:1062–9. McBride DJ, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes chromosome cancer. 2010;49:1062–9.
43.
Zurück zum Zitat Leary RJ, et al Development of personalized tumor biomarkers using massively parallel sequencing. Sci Translational Med. 2010;2:20ra14. Leary RJ, et al Development of personalized tumor biomarkers using massively parallel sequencing. Sci Translational Med. 2010;2:20ra14.
44.
Zurück zum Zitat Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013;10:191–210.PubMedCrossRef Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013;10:191–210.PubMedCrossRef
45.
Zurück zum Zitat Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. Clin Cancer Res. 2012;18:23–32.PubMedCrossRef Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. Clin Cancer Res. 2012;18:23–32.PubMedCrossRef
46.
Zurück zum Zitat O’Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29:Abstr. 1007, presented data—ASCO Annual Meeting 2011. O’Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29:Abstr. 1007, presented data—ASCO Annual Meeting 2011.
47.
Zurück zum Zitat Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res. 2007;13:7264–70.PubMedCrossRef Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res. 2007;13:7264–70.PubMedCrossRef
48.
Zurück zum Zitat Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst. 2012;104:975–81.PubMedCrossRef Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst. 2012;104:975–81.PubMedCrossRef
49.
Zurück zum Zitat De Palma M, Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol. 2012;6:111–27.PubMedCrossRef De Palma M, Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol. 2012;6:111–27.PubMedCrossRef
50.
Zurück zum Zitat Buyse M, Sargent DJ, Grothey A, Matheson A, De Gramont A. Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309–17.PubMedCrossRef Buyse M, Sargent DJ, Grothey A, Matheson A, De Gramont A. Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309–17.PubMedCrossRef
51.
Zurück zum Zitat Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W, Robinson N. Lost in knowledge translation: time for a map? J Contin Educ Health Prof. 2006;26:13–24.PubMedCrossRef Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W, Robinson N. Lost in knowledge translation: time for a map? J Contin Educ Health Prof. 2006;26:13–24.PubMedCrossRef
52.
Zurück zum Zitat Sung NS, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003;289:1278–87.PubMedCrossRef Sung NS, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003;289:1278–87.PubMedCrossRef
53.
Zurück zum Zitat Westfall J, Mold J, Fagnan L. Practiced-based-research—“Blue Highways” on the NIH roadmap. JAMA. 2007;297:403–6.PubMedCrossRef Westfall J, Mold J, Fagnan L. Practiced-based-research—“Blue Highways” on the NIH roadmap. JAMA. 2007;297:403–6.PubMedCrossRef
54.
Zurück zum Zitat DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol. 2007;25:209–16.PubMedCrossRef DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol. 2007;25:209–16.PubMedCrossRef
55.
Zurück zum Zitat Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.PubMedCrossRef Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.PubMedCrossRef
56.
Zurück zum Zitat Baselga J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.PubMedCrossRef Baselga J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.PubMedCrossRef
57.
Zurück zum Zitat Beyond the pill. The economist. 2007;October 25. Beyond the pill. The economist. 2007;October 25.
58.
Zurück zum Zitat Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med. 2009;15:502–7.PubMedCrossRef Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med. 2009;15:502–7.PubMedCrossRef
59.
Zurück zum Zitat Pugliano L, Fumagalli D, Irrthum A, Schenk B, Saini KS, Dolci SM, Arahmani A, Piccart MJ, Bucur A. Integrate: a new model in collaborative breast cancer research. Advanced Breast Cancer Conference 1. 2011:Poster PO43. Pugliano L, Fumagalli D, Irrthum A, Schenk B, Saini KS, Dolci SM, Arahmani A, Piccart MJ, Bucur A. Integrate: a new model in collaborative breast cancer research. Advanced Breast Cancer Conference 1. 2011:Poster PO43.
60.
Zurück zum Zitat Oestreicher N, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005;7:380–9.PubMedCrossRef Oestreicher N, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005;7:380–9.PubMedCrossRef
61.
Zurück zum Zitat Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11:313–24.PubMed Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11:313–24.PubMed
62.
Zurück zum Zitat Lo SS, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010;28:1671–6.PubMedCrossRef Lo SS, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010;28:1671–6.PubMedCrossRef
63.
Zurück zum Zitat Finak G, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–27.PubMedCrossRef Finak G, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–27.PubMedCrossRef
64.
Zurück zum Zitat Desmedt C, et al. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin Cancer Res. 2012;18:1004–14.PubMedCrossRef Desmedt C, et al. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin Cancer Res. 2012;18:1004–14.PubMedCrossRef
65.
Zurück zum Zitat Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8:R157.CrossRef Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8:R157.CrossRef
66.
Zurück zum Zitat Yau C, et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010;12:R85. Yau C, et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010;12:R85.
67.
Zurück zum Zitat Liedtke C, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81.PubMedCrossRef Liedtke C, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81.PubMedCrossRef
68.
Zurück zum Zitat Chang J, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 2000;89:2145–52.PubMedCrossRef Chang J, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 2000;89:2145–52.PubMedCrossRef
69.
Zurück zum Zitat Gámez C, Flamen P, Holmes E, Robles J, Gebhart G, Di Cosimo S, Eidtmann H, Piccart-Gebhart M, Baselga J, de Azambuja E, Team, on behalf of the N.-A. S. FDG-PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and their Combination in HER2 Positive Breast Cancer Patients: The Neo-ALTTO PET Study Results. European Society for Medical Oncology Annual Meeting. 2011:Abstr. S–S013. Gámez C, Flamen P, Holmes E, Robles J, Gebhart G, Di Cosimo S, Eidtmann H, Piccart-Gebhart M, Baselga J, de Azambuja E, Team, on behalf of the N.-A. S. FDG-PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and their Combination in HER2 Positive Breast Cancer Patients: The Neo-ALTTO PET Study Results. European Society for Medical Oncology Annual Meeting. 2011:Abstr. S–S013.
70.
Zurück zum Zitat Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat. 2005;94:115–22.PubMedCrossRef Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat. 2005;94:115–22.PubMedCrossRef
71.
Zurück zum Zitat Gnant M, Baselga J, Rugo HS, Noguchi S, Pritchard KI, Burris HA, Piccart-Gebhart MJ, Hart LL, Eakle JF, Mukai H, Iwata H, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl DE, Hortobagyi GN. Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). J Clin Oncol. 2012;30:Abstr. 512. Gnant M, Baselga J, Rugo HS, Noguchi S, Pritchard KI, Burris HA, Piccart-Gebhart MJ, Hart LL, Eakle JF, Mukai H, Iwata H, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl DE, Hortobagyi GN. Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). J Clin Oncol. 2012;30:Abstr. 512.
72.
Zurück zum Zitat Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751–7.PubMedCrossRef Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751–7.PubMedCrossRef
Metadaten
Titel
Personalized medicine for breast cancer: dream or reality?
verfasst von
Lina Pugliano
Dimitrios Zardavas
Martine Piccart, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0104-x

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe